Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Mersana (MRSN) PT Lowered to $11 at Wedbush
March 12, 2019 7:19 AM EDTWedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $11.00 (from $15.00) while maintaining a Outperform rating.
Ph 1b dose escalation data from MRSNs XMT-1536 is expected in 2Q19MRSN set to unveil their next clinical candidate in H2:19... More